… Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus
infection in adult renal transplant recipients. Am J Transplant. 2006;6(9):2134-43, 10.1111/ajt.…

… CMV infection is essentially unknown in transplant recipients until cytotoxic drugs such
as azathioprine and cyclophosphamide were added to theimmunosuppressive treatment …

… recipients is a major goal in the transplantation setting. With respect to universal prophylaxis
of HCMV infection in transplant recipients, the … of HCMV infection in transplant recipients, the …

… have assumed increasing importance in the care of transplant recipients … CMV infection
in solid-organ transplant recipients and describes the varied clinical manifestations of CMV …

… were significantly lower in renal transplant recipients who had asymptomatic CMV infection
compared with those who had no CMV infection. Thus, CMV infection may decrease insulin …

… of the molecular biology and epidemiology of CMV infection and in our ability to … , CMV
remains the "troll of transplantation," In this article I outline the epidemiology of CMV infection in …

… preemptive treatment of CMV infection in liver transplant recipients, including high-risk CMV
D+/… not be completely effective in CMV D+/R- liver recipients since the replication kinetics of …

… transplant recipients. For the purpose of developing consistent reporting of CMV in clinical
trials, definitions of CMV infection … This study seeks to update the definitions of CMV on the …

… , etc.) and indirect effects (rejection, infections by other microorganisms and graft dysfunction).
In … aspects of CMV infection in SOT recipients, including pre- and post-transplant diagnosis …

… is an important cause of morbidity and mortality in transplant recipients. CMV infection
commonly results from the reactivation of a latent infection. Using a set of monoclonal anti-…